Thursday 28 November 2013

New Anti-IL-6 Biologic Succeeds in RA

(MedPage Today) -- The investigational subcutaneous interleukin (IL)-6 blocker sarilumab plus methotrexate was effective in reducing the signs and symptoms of rheumatoid arthritis in a phase III trial, the drug's makers announced Friday. (Source: MedPage Today Geriatrics)

Source: http://www.medworm.com/index.php?rid=7778969&cid=u_0_18_f&fid=38001&url=http%3A%2F%2Fwww.medpagetoday.com%2FRheumatology%2FArthritis%2F43079

school for phlebotomist phlebotomy colleges phlebotomy training classes

No comments:

Post a Comment